• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stability of lyophilized Meningococcal A conjugate vaccine, (MenAfriVac ™) at elevated temperatures to support controlled temperature chain (CTC) claim
Biologicals. 2023 Aug 8;83:101698. doi: 10.1016/j.biologicals.2023.101698. Online ahead of print.ABSTRACTMeningococcal A Conjugate Vaccine (MenAfriVac) is the world's first Monovalent Conjugate Vaccine against Neisseria Meningitidis serogroup A which has obtained Controlled Temperature Chain (CTC) label claim of "stable upto 40°C for 4 days prior to reconstitution" developed by Serum Institute of India Pvt. Ltd. Pune, India and the vaccine was granted permission from World health Organization. This paper elucidates and talks about the layout of various studies performed to characterize the product to declare as CTC at the...
Source: Biologicals : Journal of the International Association of Biological Standardization - August 10, 2023 Category: Biotechnology Authors: Sunil Gairola Prashant Bonde Pankaj Sharma Sameer Kale Sunil Goel Suresh Jadhav Source Type: research

Cardiorespiratory Adverse Events after First Vaccination in Preterm Neonates With Gestational Age & lt;30 Weeks
CONCLUSION: Adverse cardiorespiratory events were uncommon after first vaccinations in very preterm neonates. Administering vaccines to these before discharge would allow monitoring for these events, especially for those who require long-term respiratory support.PMID:37211893
Source: Indian Pediatrics - May 22, 2023 Category: Pediatrics Authors: Hima Surendran Femitha Pournami Anila V Panackal Ajai Kumar Prithvi Jyothi Prabhakar Naveen Jain Source Type: research

Estimation of baseline IgG antibody levels to 23 pneumococcal vaccine-type capsular polysaccharides in healthy vaccine na ïve Indian adults
Vaccine. 2023 May 10:S0264-410X(23)00497-8. doi: 10.1016/j.vaccine.2023.04.074. Online ahead of print.ABSTRACTSince immunological responses to pneumococcal vaccines are assessed by a fold-increase in antibody levels relative to pre-immunization levels, it is therefore critical to determine baseline antibody levels to establish putative threshold as a measure of normal response. Herein, for the first time, we measured baseline IgG antibody levels in 108 healthy unvaccinated Indian adults using WHO-recommended ELISA. Median baseline IgG concentration ranged between 0.54 µg/mL to 12.35 µg/mL. Highest levels of baseline caps...
Source: Vaccine - May 12, 2023 Category: Allergy & Immunology Authors: Vandana Govindan Feroze A Ganaie Shincy M Ramakrishnan Shilpa Ravindran Akhila M Mavuppadi K L Ravikumar Source Type: research

Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix < sup > TM < /sup > and Prevenar13 < sup > TM) < /sup > ) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children
CONCLUSION: The reduced dose schedule (1 + 1) of PCV13 results in significant VT-carriage reduction in the second year of life. Immune protection provided by 1 + 1 schedules of PCV10 and PCV13 in the second year of life is comparable to WHO-recommended 3-dose schedules.PMID:37045679 | DOI:10.1016/j.vaccine.2023.04.008
Source: Vaccine - April 12, 2023 Category: Allergy & Immunology Authors: Anand Kawade Girish Dayma Aditi Apte Nilima Telang Meenakshi Satpute Emma Pearce Lucy Roalfe Rakesh Patil Yanyun Wang Navideh Noori Arun Gondhali Sanjay Juvekar Assaf P Oron Sonali Sanghavi David Goldblatt Ron Dagan Ashish Bavdekar Source Type: research

Pages: 1  2  3  4  5